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Abstract 
The UK hematology community has an established process for identifying the need for a guideline, 
producing and disseminating it. TheBritish Committee for standards in Haematology (BCSH) was 
formed in 1964with the first published guideline in 1984. . The resultant library  of documents 
includes aspects of laboratory practice in areas such as blood transfusion to highly complex clinical 
management guidelines. These are published in peer review journals but are also available via a web 
based platform with free access (http://www.bcshguidelines.com). In this article we discuss the 
process and history of the production of these guidelines with particular reference to those for 
myeloproliferative neoplasms. 
Introduction 
Guidelines are a way of providing a way of providing suggestions for the diagnosis and 
management of patients. They are usually are usually compiled by those with some 
expertise in the particular condition. Guidelines may be produced as a statement of opinion 
from experts but more recently and probably more appropriately those formulating 
guidelines tend to use methodology to formally assess the evidence of the condition. 
The BCSH guideline process 
The British Committee for Standards in Haematology (BCSH) was formed in 1964 and 
worked on standards for laboratory practice. After various negotiations over years BCSH 
became a subcommittee of the British Society for Haematology (BSH) in 1976. The first 
published guideline dates to 1984.. BCSH)  has been producing guidance for haematologists 
since that time. These guidelines were initially focussed upon laboratory practice guidelines 
but subsequently moved into areas of clinical practice over the following years. The primary 
aim of the BCSH guideline process is to provide haematologists with up-to-date advice on 
the diagnosis and treatment of haematological disease. The BCSH process or methodology 
for guideline production has evolved over the subsequent years. Laboratory guidelines were 
mainly methodologically based but clinical guidelines review literature and access and grade 
evidence using a standardised process.  
Currently there are four BCSH task forces general haematology, haemostasis and 
thrombosis, blood transfusion and haemato-oncology covering the main areas of 
haematology practice. Currently guidelines are produced in three different formats. Firstly, 
evidence-based guidance is produced using a standardised process of conducting systematic 
review(s) developed following a primary systematic review of the evidence. Secondly 
evidence–based guideline  referencing other previously published evidence-based  guideline 
produced by systematic review for instance international guideline and thirdly  guidance 
and recommendations where there is less robust evidence but for which a degree of 
consensus is likely to be benifical to patient care. 
BCSH guideline writing groups are composed of appropriate experts (consultants or senior 
healthcare scientists in practice in the UK), a member of the relevant task force and 
representative of relevant professional and patient bodies. The members of the writing 
group are approved by the task force. After formation of the writing group, databases are 
searched with appropriate keywords, search period and inclusion and exclusion criteria. All 
references are sourced and evaluated by the group and recommendations formulated. An 
audit tool is attached to each guideline for assessment of adherence to the guidance. The 
GRADE nomenclature is currently in use for evaluating evidence and assessing the strength 
of recommendations1. 
When complete guidelines are reviewed  by both the relevent taskforce and then by so-
called “sounding boards” which are composed of practising haematologists and provide 
peer review. When the final guideline is agreed it is posted on the website. The aim is then 
to publish in a peer reviewed journal, usually the British Journal for Haematology.  
BCSH Myeloproliferative Neoplasms Guidelines 
The BCSH Myeloproliferative Neoplasm (MPN) guidelines are all evidence based guidelines 
formulated following primary review of the evidence. When there is a lack of evidence then 
and expert opinion is agreed. In 2005 the first guideline in MPNs was produced and 
published. This and all subsequent guidelines in MPNs were developed by various groupings 
of MPN interested haematologists working in the Myeloproliferative Disorders Study Group 
which became an official subgroup of the National Cancer Research Institute (NCRI), the 
NCRI Myeloproliferative Disorders Subgroup in 2006. Experts from other areas were co-
opted as required.  
The first guideline produced and published in 2005 was a comprehensive guideline on the 
diagnosis, investigation and management of polycythaemia/erythrocytosis. It covered the 
diagnostic processes for the investigation of erythrocytosis in detail. The guideline group 
included expert haematologists and experts from other disciplines including respiratory 
medicine and paediatric cardiology. The management of Polycythaemia Vera (PV) was 
included with review of all randomised clinical trials and then recommendations on 
treatment and cytoreductive therapies were formulated. Management of thrombotic and 
haemorrhagic complications, pruritus, and pregnancy in PV was also considered. The 
guideline document then formulated the recommended management of other types of 
erythrocytosis, apparent erythrocytosis, idiopathic erythrocytosis, high oxygen affinity 
haemoglobins hypoxic pulmonary disease, cyanotic congenital heart disease and post renal 
transplant erythrocytosis2. As such this guideline, presented advice for a large spectrum of 
clinical conditions associated with an erythrocytosis. Very soon after the publication of this 
guideline the acquired JAK2 mutation was discovered in many patients with MPN3 and this 
had major implications on the diagnostic pathway in PV. This evidence was evaluated and 
new diagnostic criteria were formulated. This was published as an amendment in 2007 and 
the website is structured so that this and other amendments are always linked with the 
original guideline4. 
Following this, thrombocytosis was tackled and in 2010 a guideline for the investigation and 
management of adults and children presenting with a thrombocytosis was published5. This 
also had a wide remit and covered all aspects of the diagnostic pathway with differential 
diagnosis. In the management of essential thrombocythaemia (ET) prognosis, risk 
stratification and thrombotic risk were considered. All therapies were reviewed and 
treatment specific recommendations made. Management of the specific circumstances, 
pregnancy, post ET myelofibrosis, leukaemia transformation, children, splanchnic vein 
thrombosis and surgery were considered.  Recommendations were also made for 
management of reactive thrombocytosis and myelodysplastic /MPN overlap disorders. 
Following this publication two further articles were published clarifying the diagnostic 
process. Firstly it was clarified that BCR-ABL1 testing should be carried out in all patients to 
ensure a diagnosis of chronic myeloid leukaemia was excluded6. The second development 
was again because of the discovery of new mutations. In the process of evaluating a patient 
for ET acquired mutations in the CALR gene supported the clonal nature of the disorder7. 
This development was incorporated into the diagnostic criteria8.  
The group then considered specifically myelofibrosis and developed a guideline for its 
diagnosis and management. This also considered the diagnostic pathway and all the 
management options including myelosuppressive therapy and bone marrow 
transplantation. Specific clinical situations including splenomegaly and extramedullary 
haematopoiesis, anaemia and the management of constitutional symptoms were evaluated. 
Management options for blast crisis, pregnancy and myelofibrosis in childhood were also 
included9. This guideline was published in 2012. Trials of JAK inhibitors were underway at 
that time and were mentioned in the guideline but the trials had not yet been published. 
When they were published they needed to be included and management advice modified in 
view of the trial result. This was published as a modification to the guideline10.  
A comprehensive guideline for the detection of JAK2V617F and other mutations was also 
prepared and published covering laboratory practice including sample issues and laboratory 
methodology and assay validation 11. At the present time guidelines for the investigation 
and management of eosinophilia and a second set of guidelines for the management of 
mast cell disorders are in preparation. 
Thus over an almost 10 years period guidelines for diagnosis and management of all aspects 
of MPN have been prepared and published primarily aimed at haematology practise in the 
United Kingdom. 
Health Care Utilization 
In a digital world, doctors including haematologists in their working environment have 
instant internet access either by desktop computer or handheld device. The BCSH guidelines 
are freely available via the BSH website. As such they are instantly available via the internet. 
In the UK, clinicians consult the guidelines frequently via the internet and often in real time 
as part of a consultation. This is evidenced by the fact that there are almost 500,000 page 
views per year from the UK to the BSH guidelines website in recent years. This is of course a 
figure for all guidelines. However, the MPN guidelines are always among those which are 
frequently visited. In 2015, the myelofibrosis guideline and the erythrocytosis guideline 
were both in the top 10 guidelines visited in the year. This is despite the fact that the 
erythrocytosis guideline dates back 10 years. In 2014 in conjunction with the British Journal 
for Haematology an app was prepared of the guidelines. Activity via the app reached a 
maximum of 9,000 downloads per month in 2015 before starting to decline.  In view the 
costs of maintaining apps this is not being taken forwards. 
 
The guidelines are all published in peer reviewed journals mainly and in the case of MPN 
guidelines exclusively in the British Journal for Haematology. This journal has universal open 
access and the guidelines are frequently accessed and downloaded in the UK and beyond 
from the journal site. The investigation and management of thrombocytosis in adults and 
children has been one of the most frequently cited and downloaded articles from the 
journal again reflecting the usefulness of these documents. 
In addition to the MPN and other BCSH guidelines being used in day to day clinical practice 
and sometimes real time during a consultation they are also used in other situations for 
example as a basis for education both of trainees, for on-going professional development 
and are  accessed by patients and representatives of the pharmaceutical industry alike. 
Furthermore currently guidelines are also produced with an associated audit tool which 
facilittates audit and standardisation of practice. Lastly guidelines are also used in the NICE 
(National Institute of Clinical Excellence) processes at least in part to inform standard 
practices in the UK and this relates not only to drug reimbursement – the practical example 
here being the approval of the JAK1/2 inhibitor ruxolitinib but may also relate to approval of 
funding for specific tests (eg implementation of and funding for molecular tests). 
International practice pattern 
While BCSH guidelines are written primarily for UK practice and are written in the context of 
the UK National Health Service they are consulted worldwide. The pattern of downloads for 
the last 12 months show Ireland (27,085), United States (13,597), India (16,311), Sri Lanka 
(15,770), Australia (11,553), Saudi Arabia (9.088), Malaysia(8,901), Pakistan (9,138), Italy 
(11,124) and others (149,880). This shows that the guidelines are widely used in a 
worldwide context and the MPN guidelines will doubtless have contributed greatly to this 
activity. For example at the time of writing the modified BCSH guidelines for myelofibrosis 
incorporate the use of ruxolitinib and were the first widely internationally available MPN 
guidelines to do so. 
Other guidelines do exist for MPN practice the most widely used are those from the ELN12, 
and also the ESMO guidelines13 which are the only other guidelines in the public domain to 
recommend the JAK inhibitor ruxolitinib. Specifically in the contact of the later therapy the 
BCSH guidelines, unlike the ESO guidelines for example, suggest practical measures for 
starting, monitoring and when to stop the therapy all of which are important for rare 
conditions when clinicians may have little experience of using newer agents. 
 
Changing process 
Although the BCSH guideline process has been highly beneficial and successful it is being 
revised and improved. The scope of searches, with comprehensive inclusion and exclusion 
criteria for articles are being planned with help from medical writers in carrying out 
searches after clear questions have been formulated. The National Institute for Clinical 
Excellence (NICE) has a process for the accreditation of guidelines. While the BCSH has not 
yet completed a comprehensive process in order to gain accreditation it is working towards 
implementation of processes in order to gain NICE accreditation. 
Under the revised system a new guideline on the diagnosis and management of PV is 
planned reviewing all the new evidence from trials of new agents in the last 10 years and 
then formulating evidence based management advice. Review of the evidence for diagnosis 
and management of secondary erythrocytosis will also be reviewed in the near future. 
Guidelines for eosinophilia and mastocytosis are in progress. 
Conclusions 
The well established BCSH process for producing guidelines has evolved since its inception in 
1987. For MPN there are 3 existing guidelines for the common philadelphia negative 
diseases ET, PV and MF these are reviewed and updatedif necessary at least every 3 years or 
sooner if required due to new findings eg the CALR mutation or new therapies eg the JAK 
inhibitor ruxolitinib. These are produced using a highly rigorous technique and peer 
reviewed through the BCSH task forces, a sounding board and then prior to publication in an 
academic journal. The benefits of such guidelines include: education, standardisation of 
practice, tool for auditing practice, and on ocassion facilitating reimbursement of novel tests 
or therapies. 
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